Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter for the Oakmark Equity and Income Fund. The equity portfolio returned 4.67%, underperforming the S&P 500 Index, with an underweight in tech stocks. The fixed income portfolio returned 1.97% outperforming the Bloomberg U.S. Aggregate Bond Index.

In the same investor letter, Oakmark Equity and Income Fund highlighted Charles River Laboratories International, Inc. (NYSE:CRL). The company offers drug discovery and safety testing services. Its shares lost 30.47% in the last 52 weeks. On July 14, 2025, CRL stock closed at $158.04 per share.

Oakmark Equity and Income Fund praised Charles River Laboratories International, Inc. (NYSE:CRL) in its investor letter, citing its leading position in preclinical research services. The company’s wide competitive moat and history of strong organic growth make it an attractive investment. The fund sees value in purchasing CRL shares below intrinsic value.

Charles River Laboratories International, Inc. (CRL) was among the mid-cap stocks insiders were buying in Q1 2025. The company’s potential as an investment was noted by 39 hedge fund portfolios. CRL is not on the list of 30 Most Popular Stocks Among Hedge Funds, with AI stocks offering greater upside potential according to data.

Read more at Yahoo Finance: Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes